Insurance Coverage for TRT: What Medicare, Private Plans, and Telehealth Actually Pay

Does Insurance Cover TRT?

Private health insurance generally covers testosterone replacement therapy when a physician documents a clinical diagnosis of hypogonadism and laboratory values confirm low testosterone. Coverage is not automatic. Most major commercial payers, including UnitedHealthcare, Aetna, Cigna, and BlueCross BlueShield plans, require the patient to meet specific clinical criteria before a claim is approved.

The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy states: "We recommend making a diagnosis of hypogonadism only in men with symptoms and signs consistent with testosterone deficiency and unequivocally low serum testosterone concentrations." That standard, once met and documented in a chart note, is the foundation of every successful insurance claim for TRT. [1]

The FDA has approved testosterone replacement specifically for male hypogonadism caused by primary hypogonadism (congenital or acquired) or hypogonadotropic hypogonadism (congenital or acquired). Coverage for age-related testosterone decline, sometimes called late-onset hypogonadism or andropause, is far less consistent across payers because the FDA label does not include it as a standalone indication. [2]

Practically speaking, a diagnosis code of E29.1 (testicular hypofunction) or E23.0 (hypopituitarism) paired with two confirmatory lab values gives a prescribing physician the documentation needed to submit a prior authorization request with a strong chance of approval.

What Prior Authorization for TRT Requires

Prior authorization (PA) is the single biggest administrative obstacle between a patient and covered TRT. Understanding what documents a plan demands speeds up approval substantially.

Most commercial plans require all of the following before approving testosterone PA requests:

Two low testosterone readings. Both must be drawn in the morning, typically before 10 a.m., on separate days. The commonly cited threshold is total testosterone below 300 ng/dL, consistent with the Endocrine Society guideline cutoff. [1] Some plans use 270 ng/dL as their internal benchmark, so checking the specific plan's medical policy document matters.

A diagnosis of primary or secondary hypogonadism. The chart must document signs and symptoms: reduced libido, fatigue, decreased muscle mass, or erectile dysfunction are the most accepted supporting symptoms.

Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels. These differentiate primary from secondary hypogonadism and are required by most PA forms to justify the prescription clinically.

Documentation that a contraindication workup was performed. This generally means a prostate-specific antigen (PSA) value and a hematocrit to rule out polycythemia before therapy starts. The Endocrine Society recommends checking PSA and hematocrit at 3 to 6 months after initiating therapy and annually thereafter. [1]

Approval timelines range from 24 hours on urgent submissions to 14 business days for standard reviews. Denials typically cite insufficient documentation rather than outright policy exclusion. Appealing a denial with an attending physician's letter and the full Endocrine Society guideline citation reverses the decision in a meaningful share of cases.

A practical PA submission framework used by HealthRX clinicians includes five elements in every prior authorization package: (1) signed office note with symptom documentation, (2) two dated morning lab reports with reference ranges, (3) LH and FSH results, (4) PSA and hematocrit values, and (5) a brief clinical rationale paragraph citing Endocrine Society 2018 criteria. Plans that receive all five elements in the initial submission show faster approval and fewer information requests.

TRT Cost Per Month: Formulation-by-Formulation Breakdown

Monthly TRT costs vary widely by formulation, whether a brand or generic is dispensed, and whether a manufacturer coupon or pharmacy discount card is applied.

Testosterone cypionate injection (generic, 200 mg/mL). This is the lowest-cost FDA-approved option. At a typical dose of 100 mg weekly or 200 mg every two weeks, a 10 mL vial lasts roughly 10 weeks. Cash price at major pharmacy chains runs $30 to $70 per vial without insurance. With GoodRx or a similar discount program, prices at some pharmacies fall below $30. [3]

Testosterone enanthate injection (generic). Pricing is similar to cypionate, roughly $35 to $80 per vial depending on the pharmacy. Both cypionate and enanthate are Schedule III controlled substances, so 90-day supplies cannot be dispensed; most states limit fills to a 30-day supply per transaction. [4]

Testosterone gel 1% (AndroGel and generics). Brand AndroGel carries a list price above $500 per month, but a generic 1% gel is available for $60 to $120 monthly at most major pharmacies. [5] Insurance plans that cover testosterone gel typically place the brand on tier 3 or tier 4 while the generic sits at tier 2, making the copay difference substantial.

Testosterone solution 2% (Axiron). Less commonly prescribed today. Cash price for the brand exceeds $400 monthly; generic axillary testosterone solution is available for approximately $80 to $140.

Testosterone pellets (Testopel). These are implanted subcutaneously every 3 to 6 months in an in-office procedure. The pellets themselves may be covered under the medical benefit rather than the pharmacy benefit. The implantation procedure carries a separate CPT code (11981) that requires its own authorization. Total cash cost ranges from $500 to $1,500 per insertion depending on the practice. [6]

Compounded testosterone. Compounded formulations, including many offered through telehealth-only TRT platforms, are not FDA-approved finished drug products and are rarely if ever reimbursed by commercial insurance or Medicare. Patients pay fully out of pocket, typically $80 to $200 per month for a compounded cypionate or enanthate vial. [7]

Medicare TRT Coverage: Part B vs. Part D

Medicare beneficiaries frequently ask whether TRT is covered. The answer depends on formulation and how it is administered.

Medicare Part D covers FDA-approved testosterone formulations when they appear on a plan's formulary and when the prescription meets the plan's coverage criteria. Most Part D plans include at least one testosterone injection in their formulary. The specific tier placement, deductible, and copay differ by plan. Beneficiaries can compare Part D formularies for their ZIP code at the Medicare Plan Finder at medicare.gov. [8]

Medicare Part B covers injectable medications that a physician administers in-office. If a patient receives a testosterone injection at a physician's office (as opposed to self-administering at home), the injection may qualify for Part B reimbursement under the "incident to" billing rules. Home self-administered injections are Part D, not Part B. [9]

Medicare does not cover compounded testosterone under any part. The CMS Medicare Prescription Drug Benefit Manual explicitly excludes bulk-manufactured compounded products from Part D coverage. [9]

For Medicare Advantage (Part C) plans, testosterone coverage mirrors the underlying Part D benefit but may include additional utilization management tools. Checking the specific plan's Evidence of Coverage document is the only reliable way to confirm what is covered and at what cost-sharing level.

A 2022 analysis of Medicare Part D claims data published in JAMA Internal Medicine found that testosterone prescriptions among men 65 and older increased by 170% between 2001 and 2011 before FDA label changes prompted a modest decline. [10] That pattern underscores how substantial a segment of the Medicare population uses covered TRT.

Online TRT Prices: What Telehealth Platforms Charge

Direct-to-consumer telehealth TRT platforms operate outside the traditional insurance system. Most do not accept insurance at all. They charge a bundled monthly or quarterly fee that covers the physician consultation, lab work, and medication.

Typical monthly pricing across major telehealth TRT platforms in 2025 breaks down as follows:

• Consultation and ongoing physician oversight: $20 to $60 per month
• Injectable testosterone (cypionate or enanthate): $30 to $80 per month shipped
• Quarterly lab panel (total testosterone, free testosterone, estradiol, hematocrit, PSA, LH, FSH): $75 to $150 per draw, billed separately by most platforms or bundled quarterly

All-in monthly cost for a telehealth TRT program typically lands between $100 and $200 monthly when lab work is amortized. Some platforms advertise entry prices below $100 monthly but charge separately for labs, which brings the real total higher.

A key distinction: platforms that prescribe only FDA-approved testosterone cypionate or enanthate at a licensed pharmacy are operating within the DEA and FDA framework. Platforms that prescribe compounded testosterone cypionate from a 503B outsourcing facility or a 503A pharmacy are providing a product that is not covered by any commercial insurer and exists in a more complex regulatory space under FDA guidance. [7]

Patients using HSA or FSA accounts can pay telehealth TRT fees with pre-tax dollars, since the IRS classifies medically prescribed testosterone as a qualified medical expense under IRS Publication 502. [11]

How to Check Whether Your Plan Covers TRT

Verifying coverage before the first prescription is filled saves time and avoids surprise bills. A step-by-step process that works across most commercial plans:

Step 1. Obtain your plan's Summary of Benefits and Coverage (SBC) or the full Evidence of Coverage document. These are available from your employer's HR portal or directly from the insurer's member portal.

Step 2. Search the plan's drug formulary. Look up testosterone cypionate, testosterone enanthate, and testosterone gel 1% by both brand and generic name. Note the tier level, any quantity limits, and whether step therapy applies.

Step 3. Call member services. Ask specifically: "Does my plan require prior authorization for testosterone cypionate prescribed for hypogonadism, and what clinical criteria must be met?" Request the medical policy number in writing.

Step 4. Ask your physician to document two morning testosterone levels below 300 ng/dL, along with LH, FSH, PSA, and hematocrit, before the PA is submitted. Incomplete PA submissions are the leading cause of initial denials. [12]

Step 5. If denied, file a formal appeal. The ACA requires insurers to provide an external review process for denied claims. The Endocrine Society guideline, combined with a physician letter explaining the specific clinical rationale, is the standard evidence package for an appeal. [1]

The Cost of Not Treating Hypogonadism: A Brief Clinical Note

The decision about whether to pay out of pocket or fight for insurance coverage has a clinical backdrop worth quantifying. Hypogonadism is associated with increased cardiovascular risk, reduced bone mineral density, and metabolic dysfunction. A 2019 study published in the Journal of Clinical Endocrinology and Metabolism found that men with total testosterone below 300 ng/dL had significantly higher rates of metabolic syndrome (odds ratio 2.09 to 95% CI 1.56 to 2.81, P<0.001) compared to eugonadal men. [13]

The T Trials (Testosterone Trials), a coordinated set of seven placebo-controlled trials (N=788 men aged 65 and older with testosterone below 275 ng/dL), showed that testosterone treatment for one year produced statistically significant improvements in sexual function, physical function, and bone mineral density versus placebo. [14] That data is published in the New England Journal of Medicine and is frequently cited in PA appeal letters to justify medical necessity.

Managing TRT Costs Without Full Insurance Coverage

When insurance will not cover TRT or when a patient chooses a telehealth-only route, several strategies reduce monthly expense.

Generic injectable testosterone. Testosterone cypionate generic is on the $4 to $30 generic list at several national pharmacy chains. Confirming availability at the specific dispensing pharmacy before the prescription is sent avoids disappointment. [3]

Manufacturer copay cards. AbbVie offers a savings card for AndroGel that reduces copay to $0 for commercially insured patients on eligible plans. Endo Pharmaceuticals offers a similar program for Testopel. These programs exclude Medicare and Medicaid beneficiaries by law. [5] [6]

GoodRx and NationalDrugCode discount programs. For cash-pay patients, GoodRx prices for testosterone cypionate 200 mg/mL (10 mL) range from $22 to $65 depending on the pharmacy. Presenting the discount card at the pharmacy counter, rather than running through insurance, sometimes yields a lower total. [3]

HSA and FSA accounts. Contributions to a Health Savings Account (HSA) reduce taxable income dollar-for-dollar. The 2025 HSA contribution limit is $4,300 for an individual and $8,550 for a family under a high-deductible health plan. TRT prescriptions, lab work, and physician consultation fees are all qualified expenses under IRS Publication 502. [11]

Splitting vials under physician supervision. Some prescribers write for a higher concentration vial with a lower per-injection dose, extending the vial across more weeks at the same pharmacy price per vial. This is legal, reduces cost, and is common practice for testosterone cypionate 200 mg/mL. Any dose adjustment must be managed by the prescribing physician.

What the FDA Label Says About Approved Indications

The FDA-approved labeling for testosterone products restricts indicated use to male hypogonadism, defined as primary hypogonadism (congenital or acquired testicular failure) or hypogonadotropic hypogonadism (congenital or acquired). [2]

In 2015, the FDA required manufacturers to add a label clarification stating that testosterone products are approved only for men with low testosterone due to a medical condition, not for use in men with age-related low testosterone where no underlying medical condition exists. The FDA also required a general warning about cardiovascular risk. [2] That 2015 label action is the primary reason insurers include "medical necessity" language in their TRT coverage policies. Physicians documenting age-related decline without a specific diagnostic code face higher rates of PA denial.

The prescribing information for testosterone cypionate injection, available on the FDA's Drugs@FDA database, provides the complete approved labeling and is the reference document most PA reviewers use. [2]